eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Companyâ€™s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
18/06/26	USD 0.000200	0.00%	1,100
17/06/26	USD 0.000200	-66.67%	251

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets Other stock markets 01:06:27 19/06/26 am AEST			5-day change	1st Jan Change
0.000200 ^USD	0.00%		-66.67%	-

11/09/24	Tyra Biosciences Names Doug Warner Chief Medical Officer	MT
08/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	CI

Market Cap	940 827.58 763.34 713.93 1.34K 88.6K 1.36K 9.17K 3.55K 43.71K 3.53K 3.45K 152K	P/E 2022	-0.78x	P/E 2023	-0.71x
Enterprise Value	2.18M 1.92M 1.77M 1.65M 3.1M 205M 3.15M 21.24M 8.23M 101M 8.17M 7.99M 352M	EV / Sales 2022	3,344,920x	EV / Sales 2023	-
Free-Float	99.75%	Yield 2022 *	-	Yield 2023	-

11/09/24	Tyra Biosciences Names Doug Warner Chief Medical Officer	MT
08/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	CI
02/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index	CI
25/06/24	Sector Update: Health Care Stocks Rise in Late Afternoon Trading	MT
25/06/24	Top Midday Decliners	MT
25/06/24	EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives	MT
24/06/24	EFFECTOR Therapeutics, Inc. Announces Cessation of Michael Byrnes, Chief Financial Officer	CI
24/06/24	Effector Therapeutics, Inc. Terminates Its Employees in Connection with the Planned Wind Down of the Company?s Operations	CI
24/06/24	Effector Therapeutics, Inc. Announces Director Resignations	CI
24/06/24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as CEO	CI
24/06/24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board	CI
20/05/24	EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer	CI
10/05/24	EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

24/08/23	HC Wainwright Starts eFFECTOR Therapeutics With Buy Rating, $5 Price Target	MT
26/05/23	Stifel Upgrades eFFECTOR Therapeutics to Buy From Hold, Adjusts Price Target to $7 From $1.30	MT
10/05/23	Credit Suisse Trims eFFECTOR Therapeutics' Price Target to $5.50 From $7, Keeps Outperform Rating	MT
10/03/23	Credit Suisse Adjusts eFFECTOR Therapeutics' Price Target to $7 From $8, Keeps Outperform Rating	MT
10/01/23	JMP Securities Trims Price Target on eFFECTOR Therapeutics to $1 From $2, Maintains Market Outperform Rating	MT

eFFECTOR Therapeutics, Inc. Stock

Stocks

EFTR

US28202V2079

Biotechnology & Medical Research

Valuation: eFFECTOR Therapeutics, Inc.

Chart: eFFECTOR Therapeutics, Inc.

Latest news : eFFECTOR Therapeutics, Inc.

Analysts' recommendations: eFFECTOR Therapeutics, Inc.

Press Releases: eFFECTOR Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: eFFECTOR Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

13/08/24	FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer	AQ
26/06/24	EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K	PU
24/06/24	EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq	AQ
04/04/24	EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	AQ
06/02/24	EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	AQ

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.02
3 years	0		22.5
5 years	0		1,010.5
10 years	0		1,010.5

Date	Insider	Type	Main position	Quantity	% Market Cap.
13/06/24	Brian Gallagher	Free	Chairman	800	0.0170%
13/06/24	Elizabeth Bhatt	Free	Director	800	0.0170%
13/06/24	Christopher Ehrlich	Free	Director	800	0.0170%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EFFECTOR THERAPEUTICS, INC.	0.00%	-66.67%	-33.33%	-100.00%	940
ARGENX SE	-7.92%	-4.05%	+53.28%	+109.11%	57.55B
WUXI APPTEC CO., LTD.	+8.55%	+17.56%	+76.80%	+82.31%	47.08B
BIONTECH SE	+0.41%	-1.31%	-13.39%	-14.88%	22.92B
INSMED INCORPORATED	+1.75%	+5.80%	-1.64%	+423.15%	22.14B
WUXI BIOLOGICS (CAYMAN) INC.	+4.17%	+8.06%	+32.41%	-14.07%	16.33B
GENMAB A/S	-0.15%	+4.15%	+27.79%	-34.36%	15.97B
EXELIXIS, INC.	+2.82%	+1.07%	+15.92%	+172.35%	12.9B
PHARMAESSENTIA CORPORATION	+5.94%	+17.05%	+143.80%	+296.09%	12.85B
MADRIGAL PHARMACEUTICALS, INC.	+0.79%	+4.07%	+82.54%	+121.16%	11.84B
Average	+1.63%	+6.26%	+38.42%	+104.09%	21.96B
Weighted average by Cap.	+0.83%	+8.48%	+47.10%	+117.80%

	2022	2023
Net sales	3.55 3.13 2.89 2.7 5.06 334.9 5.15 34.67 13.43 165.2 13.34 13.05 574.78	-
Net income	-22.66M -19.95M -18.41M -17.21M -32.25M -2.14B -32.86M -221M -85.67M -1.05B -85.1M -83.25M -3.67B	-35.81M -31.53M -29.08M -27.2M -50.96M -3.38B -51.91M -349M -135M -1.67B -134M -132M -5.79B
Net Debt	-6.03M -5.31M -4.9M -4.58M -8.58M -568M -8.74M -58.84M -22.79M -280M -22.64M -22.15M -975M	2.18M 1.91M 1.77M 1.65M 3.1M 205M 3.15M 21.23M 8.22M 101M 8.17M 7.99M 352M